Adipogen/FK-506/AG-CN2-0047-M005/5 mg
来自 :
发布时间：2025-04-04
More Information Product Details
Synonyms | Tacrolimus; Fujimycin |
Product Type | Chemical |
Properties
Formula | C44H69NO12 . H2O |
MW | 804.0 . 18.0 |
Merck Index | 14: 9025 |
CAS | 109581-93-3 |
RTECS | KD4200000 |
Source/Host Chemicals | Isolated from Streptomyces FCZ0311. |
Purity Chemicals | ≥98% |
Appearance | White to off-white solid. |
Solubility | Soluble in DMSO, ethanol, methanol, ethyl acetate or acetone. Insoluble in water. |
Identity | Determined by MS and IR. |
InChi Key | NWJQLQGQZSIBAF-CBLXODBSSA-N |
Shipping and Handling
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light. |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents
MSDS ![](\"https://www.ebiomall.com/images/adipogen/download.png\") Download PDF |
Product Specification Sheet
Datasheet | Download PDF |
- Potent immunosuppressant (as cyclosporin A and rapamycin) [1-3].
- Suppresses proliferation of cytotoxic T cells and inhibits the production of T cell-derived mediators such as interleukin-2 (IL-2) [2, 4].
- Forms a complex with FK-506 binding protein 12 (FKBP12). Inhibits the activity of the calcium/calmodulin-dependent protein phosphatase 2B (PP2B; calcineurin), leading to disruption of T cell activation [2, 4, 6, 7].
- Prevents rejection of transplanted organs [3].
- Anti-inflammatory compound in the treatment of several inflammatory skin diseases (e.g. atopic dermatitis) and with potential anti-rheumatic activity (rheumatoid arthritis) [5, 9].
- Neuroprotective. Regulates nitric oxide neurotoxicity. Neurotransmitter. Ca2+ release compound [8].
- NF-κB suppressor by induction of unfolded protein response (UPR) [11].
- Anti-cancer compound. Apoptosis inducer [10, 12].
Product References
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics: T. Kino, et al.; J. Antibiot. (Tokyo) 40, 1249 (1987) Cyclosporin A, FK506 and rapamycin: more than just immunosuppression: J. Kunz & M.N. Hall; TIBS 18, 334 (1993) Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology: B.E. Bierer, et al.; Curr. Opin. Immunol. 5, 763 (1993)The actions of cyclosporin A and FK506 on T-lymphocyte activation: P.S. Mattila; Biochem. Soc. Trans. 24, 45 (1996) (Review)FK506 in the treatment of inflammatory skin disease: promises and perspectives: G. Michel, et al.; Immunol. Today 17, 106 (1996) (Review)The mechanism of action of cyclosporin A and FK506: S. Ho, et al.; Clin. Immunol. Immunopathol. 80, S40 (1996) (Review)FK506, an immunosuppressant targeting calcineurin function: F.J. Dumont; Curr. Med. Chem. 7, 731 (2000) (Review)FK506 and its analogs - therapeutic potential for neurological disorders: A. Klettner & T. Herdegen; Curr. Drug Targets CNS Neurol. Disord. 2, 153 (2003) (Review)A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis: S. Miyata, et al.; Inflamm. Res. 54, 1 (2005) (Review)Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics: K. Iwasaki; Drug Metab. Pharmacokinet. 22, 328 (2007) (Review)Suppression of NF-kappaB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response: S. Du, et al.; J. Immunol. 182, 7201 (2009)FK506 binding proteins as targets in anticancer therapy: S. Romano, et al.; Anticancer Agents Med. Chem. 10, 651 (2010) (Review)本文链接： http://adipogen.immuno-online.com/view-1469107742.html
